Autopsy report · NCT02906774
Fecal Transplant for MDR Pathogen Decolonization
Cause of deathOther
“This observational study has been transitioned to a clinical trial and is now registered at (NCT04181112).”
Life of this trial
- Registered 4 months after it had already started.
- Ran for about 3 years 7 months before it stopped.
- 3 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Sponsor
- University of British Columbia
- Sponsor type
- University, hospital or other
- Conditions
- Multi-antibiotic Resistance
- Interventions
- Fecal microbiota transplantation (FMT)
- Participants
- 3
- Sites
- 1
- Countries
- Canada
Trials that died the same way
- Combined Therapeutic Air Mixture and Electrical Stimulation to Improve Breathing and Hand Function in Spinal Cord Injury
“The study evolved into a multi day clinical trial and was recently awarded an extramural funding. The new study will begin enrollment in late August 2025” - Vaping High vs. Low Nicotine E-Liquid
“Please see NCT04053868 for the current version of this study” - A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
“Replaced with another clinical trial.” - Phase II Study of TAEST16001 in Soft Tissue Sarcoma
“The study was terminated due to initiation of a new clinical trial with an updated study design.” - Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I
“All three subjects dosed in the study have rolled over to the Long-Term Follow-up Study IVPRP-LT01 (NCT04628871)”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.